Improving diagnostic accuracy and treatment options for equine PPID. Equine Pituitary Pars Intermedia Dysfunction (PPID) is a common, chronic and potentially life-threatening disease of older horses and ponies. Although a treatment is available, the disease is poorly understood and there are some concerns that the current diagnostic technology is not delivering accurate results. Thus, this project aims to develop a more accurate diagnostic test for PPID, while exploring the relationship between ....Improving diagnostic accuracy and treatment options for equine PPID. Equine Pituitary Pars Intermedia Dysfunction (PPID) is a common, chronic and potentially life-threatening disease of older horses and ponies. Although a treatment is available, the disease is poorly understood and there are some concerns that the current diagnostic technology is not delivering accurate results. Thus, this project aims to develop a more accurate diagnostic test for PPID, while exploring the relationship between PPID and metabolic syndrome, to generate new insights into the cause and consequences of both diseases. As an added benefit, the project will assist horseracing laboratories to improve their detection methods for peptide doping in younger competition horses.
Read moreRead less
Chemo-prevention of tropical canine parasitoses and vector-borne diseases. This project will determine the prevalence and diversity of established, emerging and novel canine vector-borne agents and endoparasites in a tropical setting by using conventional and next generation molecular diagnostic tools. It will fill an important gap by providing independently-verified evidence on how well canine anti-parasitic products marketed in Australia and Asia by Bayer Animal Health, perform in high-infecti ....Chemo-prevention of tropical canine parasitoses and vector-borne diseases. This project will determine the prevalence and diversity of established, emerging and novel canine vector-borne agents and endoparasites in a tropical setting by using conventional and next generation molecular diagnostic tools. It will fill an important gap by providing independently-verified evidence on how well canine anti-parasitic products marketed in Australia and Asia by Bayer Animal Health, perform in high-infection pressure settings, as a chemo-preventative for these disease agents. Tropical regions spanning northern Australia and Southern Asia are highly conducive to a plethora of canine vector-borne and parasitic pathogens that cause significant morbidity and mortality in dogs. Many of these agents also pose a risk to public health. The outcomes will be directly translated to best-practice guidelines for the advancement of companion animal (and indirectly human) health and welfare.Read moreRead less